Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 29;16(19):3331.
doi: 10.3390/cancers16193331.

Demographic and Clinical Characteristics of Malignant Solitary Fibrous Tumors: A SEER Database Analysis

Mattia Luca Piccinelli  1   2   3 , Kyle Law  1 , Reha-Baris Incesu  1   4 , Stefano Tappero  1   5   6 , Cristina Cano Garcia  1   7 , Francesco Barletta  1   8 , Simone Morra  1   9 , Lukas Scheipner  1   10 , Andrea Baudo  1   3   11 , Zhe Tian  1 , Stefano Luzzago  2   12 , Francesco Alessandro Mistretta  2   12 , Matteo Ferro  2 , Fred Saad  1 , Shahrokh F Shariat  13   14   15   16 , Luca Carmignani  11   17 , Sascha Ahyai  10 , Nicola Longo  9 , Alberto Briganti  8 , Felix K H Chun  7 , Carlo Terrone  5   6 , Derya Tilki  4   18   19 , Ottavio de Cobelli  2   12 , Gennaro Musi  2   12 , Pierre I Karakiewicz  1
Affiliations

Demographic and Clinical Characteristics of Malignant Solitary Fibrous Tumors: A SEER Database Analysis

Mattia Luca Piccinelli et al. Cancers (Basel). .

Abstract

Background/objectives: Solitary fibrous tumors (SFTs) represent a rare mesenchymal malignancy that can occur anywhere in the body. Due to the low prevalence of the disease, there is a lack of contemporary data regarding patient demographics and cancer-control outcomes.

Methods: Within the SEER database (2000-2019), we identified 1134 patients diagnosed with malignant SFTs. The distributions of patient demographics and tumor characteristics were tabulated. Cumulative incidence plots and competing risks analyses were used to estimate cancer-specific mortality (CSM) after adjustment for other-cause mortality.

Results: Of 1134 SFT patients, 87% underwent surgical resection. Most of the tumors were in the chest (28%), central nervous system (22%), head and neck (11%), pelvis (11%), extremities (10%), abdomen (10%) and retroperitoneum (6%), in that order. Stage was distributed as follows: localized (42%) vs. locally advanced (35%) vs. metastatic (13%). In multivariable competing risks models, independent predictors of higher CSM were stage (locally advanced HR: 1.6; metastatic HR: 2.9), non-surgical management (HR: 3.6) and tumor size (9-15.9 cm HR: 1.6; ≥16 cm HR: 1.9).

Conclusions: We validated the importance of stage and surgical resection as independent predictors of CSM in malignant SFTs. Moreover, we provide novel observations regarding the independent importance of tumor size, regardless of the site of origin, stage and/or surgical resection status.

Keywords: competing risks analyses; solitary fibrous tumor; tumor-size cut-offs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Whisker plots depicting the distribution of patients diagnosed with malignant solitary fibrous tumors, as recorded in the 2000–2019 Surveillance, Epidemiology, and End Results database: (a) age at diagnosis according to tumor site of origin; (b) age at diagnosis according to race/ethnicity; (c) tumor size (mm) according to tumor site of origin.
Figure 2
Figure 2
Bar plot depicting the distribution of patients diagnosed with malignant solitary fibrous tumors, as recorded in the 2000–2019 Surveillance, Epidemiology, and End Results database: (a) stage according to site; (b) surgical resection according to site; (c) surgical resection according to stage.
Figure 3
Figure 3
Cumulative incidence plots depicting cancer-specific mortality and other-cause mortality over 10 years in patients diagnosed with malignant solitary fibrous tumors in 2000–2019 according to the Surveillance, Epidemiology, and End Results database (a) overall and according to (b) stage; (c) surgical resection status; (d) tumor size.
Figure 3
Figure 3
Cumulative incidence plots depicting cancer-specific mortality and other-cause mortality over 10 years in patients diagnosed with malignant solitary fibrous tumors in 2000–2019 according to the Surveillance, Epidemiology, and End Results database (a) overall and according to (b) stage; (c) surgical resection status; (d) tumor size.
Figure 3
Figure 3
Cumulative incidence plots depicting cancer-specific mortality and other-cause mortality over 10 years in patients diagnosed with malignant solitary fibrous tumors in 2000–2019 according to the Surveillance, Epidemiology, and End Results database (a) overall and according to (b) stage; (c) surgical resection status; (d) tumor size.
See this image and copyright information in PMC

References

    1. Gold J.S., Antonescu C.R., Hajdu C., Ferrone C.R., Hussain M., Lewis J.J., Brennan M.F., Coit D.G. Clinicopathologic Correlates of Solitary Fibrous Tumors. Cancer. 2002;94:1057–1068. doi: 10.1002/cncr.10328. - DOI - PubMed
    1. de Bernardi A., Dufresne A., Mishellany F., Blay J.Y., Ray-Coquard I., Brahmi M. Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond. Cancers. 2022;14:1064. doi: 10.3390/cancers14041064. - DOI - PMC - PubMed
    1. Machado I., Giner F., Cruz J., Lavernia J., Marhuenda-Fluixa A., Claramunt R., López-Guerrero J.A., Navarro S., Ferrandez A., Bujeda Á.B., et al. Extra-Meningeal Solitary Fibrous Tumor: An Evolving Entity with Chameleonic Morphological Diversity, a Hallmark Molecular Alteration and Unresolved Issues in Risk Stratification Assessment. Histol. Histopathol. 2023;38:1079–1097. doi: 10.14670/HH-18-608. - DOI - PubMed
    1. Fletcher C.D.M. The Evolving Classification of Soft Tissue Tumours—An Update Based on the New 2013 WHO Classification. Histopathology. 2014;64:2–11. doi: 10.1111/his.12267. - DOI - PubMed
    1. Frith A.E., Hirbe A.C., Van Tine B.A. Novel Pathways and Molecular Targets for the Treatment of Sarcoma. Curr. Oncol. Rep. 2013;15:378–385. doi: 10.1007/s11912-013-0319-3. - DOI - PubMed